TRIAL DATA
Final overall survival analysis of CheckMate-8HW supports nivolumab plus ipilimumab in first-line MSI-H/dMMR metastatic CRCThe phase 3 CheckMate-8HW trial presented final overall survival results at ESMO 2026, evaluating nivolumab plus ipilimumab versus nivolumab monotherapy or chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer. (Targeted Oncology)